This post was originally published on The Legal Glass Substack and republished with permission. Please follow Rita on Substack for more medical freedom content.

Nearly a year into an administration run by the very people who exposed the failures of the Covid response—Robert F. Kennedy Jr. at HHS, Marty Makary at FDA, and Jay Bhattacharya at NIH—many assumed the mRNA era would finally be paused, audited, or dismantled.

Instead, the opposite has occurred. New mRNA products continue to advance:

• An mRNA RSV vaccine already approved
• mRNA flu formulations in late-stage trials
• Self-amplifying mRNA (sa-mRNA) platforms under active development
• Another Covid booster moving forward under Fast Track

For those who spent years warning that the danger was not just the spike protein but the platform itself—the lipid nanoparticles, the modified mRNA, the systemic biodistribution—this feels like a continuing nightmare.

So why is this happening?

Why are reformers allowing it?

And why, despite mounting evidence of platform-level risks, is mRNA still treated as if its safety were settled science rather than an urgent, unresolved question?

This essay explains how the platform was declared “safe” before the evidence existed, who made those decisions, what regulators already knew, and why the machinery keeps running even now. Most importantly, it addresses what almost no one in power will say out loud:

The mRNA platform is now structurally locked in—legally, financially, politically, and bureaucratically—unless the public forces a reversal.

What mRNA Originally Was — and What It Wasn’t

Before 2020, mRNA was not a vaccine platform. It was an experimental gene-delivery tool used almost exclusively in cancer therapeutics—and even there, handled with caution.

In oncology, mRNA was treated as high-risk. Researchers openly acknowledged its core problems:

• Lipid nanoparticles (LNPs) were inflammatory.
• Modified mRNA persisted far longer than natural mRNA.
• Protein expression was unpredictable and tissue-specific.
• Repeat dosing risked immune exhaustion and tolerance.

Everyone serious in the field understood the same thing: mRNA was promising but far too unstable and unpredictable to give to healthy people, let alone to entire populations in mass campaigns.

Then 2020 arrived.

The same technology that had been confined to cancer trials was suddenly repackaged as a universal “platform” for vaccination. The science had not been transformed in a year. What changed was the incentive structure. The agencies stoking public fear of a novel virus were the same agencies eager to push mRNA from fringe biotech into global ubiquity.

Safety wasn’t proven—it was declared.

mRNA didn’t rise to dominance because it was the safest or best-understood option. It rose because it was strategically useful: easy to manufacture, easy to re-code, easy to frame as a futuristic breakthrough—and easy to shield under emergency powers.

Once that decision was made, everything downstream followed from a single move: the delivery system itself was treated as validated long before the science ever caught up.

Who Decided mRNA Would Be the Covid Vaccine Platform?

The public was told that Pfizer and Moderna “developed” their Covid vaccines in record time. In reality, the decision to use mRNA as the primary vaccine mechanism came from the U.S. government—specifically, from the biodefense complex that had been funding mRNA for years and was waiting for the moment to push it into the mainstream.

BARDA (Biomedical Advanced Research and Development Authority) had already invested heavily in Moderna long before Covid. Moderna was essentially a BARDA-incubated company. When Covid appeared, BARDA didn’t run an open competition among platforms. It chose to double down on the bet it had already made, elevating mRNA as the central “rapid-response” solution.

The Department of Defense, through DARPA and the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, had likewise been funding mRNA for over a decade as part of its “countermeasure” ambitions. When a pandemic was declared, DoD didn’t ask which platform was safest. It asked which platform could be scaled and deployed fastest under a national-security umbrella. mRNA fit that strategy: a plug-and-play system for rapid biodefense manufacturing.

The NIH and NIAID were not neutral arbiters either. NIH held key patents on Moderna’s technology and on elements of the stabilized spike design, meaning federal scientists and institutions stood to receive royalties if the platform succeeded. Fauci’s team helped choose the antigen, shape the trial structure, and legitimize the whole effort. NIH was not just “following the science.” It was financially entangled in the outcome.

Then the White House made it official. Operation Warp Speed—an alliance of HHS, DoD, BARDA, NIH, and the executive branch—framed mRNA as the flagship American solution. The federal government would fund development, guarantee purchases, indemnify manufacturers, accelerate regulatory timelines, and quietly sideline competing platforms or repurposed drugs.

This was not a neutral scientific derby.

It was a policy decision made at the highest levels to elevate mRNA as the primary pandemic technology—and to protect it.

Science didn’t choose mRNA.

Power did.

The Pivotal Shift: Treating mRNA as a “Platform Technology”

The most consequential move happened inside the FDA during the Covid emergency-use process. Under Peter Marks, the Center for Biologics Evaluation and Research (CBER) began treating Pfizer’s and Moderna’s products not as one-off biologics, but as a “platform”: a reusable scaffold of LNP + modified mRNA to which future antigens could be attached.

In practice, that meant a quiet but radical assumption:

If the LNP-mRNA system is acceptable once, its safety can be assumed for all future products built on the same platform.

Operation Warp Speed contracts and internal guidance documents echoed this logic. mRNA was classified as a “rapidly adaptable platform,” and regulators began to treat future vaccines as minor modifications rather than fundamentally new products. Prior toxicology and biodistribution data could be reused. Antigen swaps could be justified via “immunobridging” (antibody comparisons in place of real-world clinical trials). Rolling review replaced the expectation of complete, long-term data.

The public never got to vote on this.

Congress never held a genuine debate on whether the foundational delivery system itself had been adequately tested.

The platform designation turned a risky gene-delivery technology into a kind of regulatory evergreen. Once it was accepted under pandemic conditions, everything built on it was allowed to inherit that acceptance by default.

What the Covid Era Revealed About the Platform Itself

Long before “safe and effective” became a slogan, regulators had already seen red-flag data about the platform—not the spike protein, but the delivery system.

They knew that LNPs were potent inflammatory adjuvants, not inert carriers. Pre-2020 literature and internal industry research described robust immune activation and tissue irritation, including hepatic stress in animal models.

They knew from Pfizer’s own Japanese biodistribution study that LNPs did not stay in the arm. They migrated to liver, spleen, adrenal glands, lymph nodes, ovaries, and other organs. Regulators saw that file in 2020 and approved the platform anyway.

They knew modified mRNA behaves differently from natural mRNA. Pseudouridine-stabilized constructs resist breakdown, persist far longer, and can drive protein production for weeks or months—and in some studies spike or mRNA fragments have been detectable even years later. Pre-Covid research warned about innate-immune interference and downstream impacts. Those concerns never got in the way of emergency authorization.

They knew expression was tissue-variable and uncontrolled. Once injected, the platform does not politely limit antigen expression to the muscle. Endothelial cells, cardiac tissue, and reproductive organs can all become manufacturing sites. This variability should have triggered caution. Instead, it was treated as manageable “uncertainty.”

Early animal studies for Moderna and Pfizer showed organ deposition, inflammatory lesions, reproductive-toxicity flags, and immune exhaustion in repeat dosing. In a sane era, this would have prompted redesign or rejection. Under emergency rules, it was reframed as acceptable risk.

Then came real-world data—and it matched the warnings.

Myocarditis and pericarditis, particularly in young males.

Menstrual disruption and signals involving ovaries.

Immune dysregulation and IgG4 class switching.

Blood-clotting abnormalities and endothelial damage.

Persistent mRNA fragments and long-lasting protein expression.

These were not “unexpected.” They were the logical consequences of the platform’s design.

The uncomfortable truth is simple:

The most concerning harms are platform-level, not spike-specific. Change the antigen, and you still carry forward the same LNP biodistribution, the same persistence, the same innate-immune disruption.

The problem is not just what mRNA tells the body to make.

The problem is how it gets there—and how long it stays.

Why They Didn’t Pause the Technology

By early 2021, the warning signs were visible in real-world surveillance, clinic data, and mechanistic studies. In any previous era, the combination of myocarditis spikes, menstrual irregularities, neurological events, and troubling biodistribution evidence would have triggered a product hold and a deep safety review.

Instead, regulators doubled down.

To pause the platform—even briefly—would have forced a series of admissions:

• that the LNP-mRNA system was never proven safe at scale;
• that red flags in pre-clinical data had been downplayed;
• that emergency authorizations had shortcut long-term toxicology;
• and that the public had been misled about where the product travels and how long it persists.

A genuine pause would also have drawn attention to the PREP Act shield and to NIH royalty conflicts, invited congressional scrutiny, and opened the door to litigation and discovery. It would have signaled that the system itself—not just this or that policy choice—was flawed.

So instead of protecting the public, institutions protected the platform. They rebranded myocarditis as “mild” and “rare,” tightened reporting definitions, sidelined dissenting physicians, and quietly wound down surveillance tools once the signal became too difficult to ignore.

The goal was not to resolve uncertainty.

It was to prevent uncertainty from undermining the platform.

The Fast Track Effect: How the Platform Turned Into a Conveyor Belt

After everything revealed during Covid about biodistribution, persistence, and immune disruption, you might expect regulators to slow the platform. Instead, they moved it onto the FDA’s fastest lanes—Fast Track, Accelerated Approval, and Priority Review.

These pathways were meant for life-threatening diseases with no good treatments. Between 2020 and 2024, they were quietly repurposed for an entire vaccine technology.

Fast Track for mRNA now means:

• Rolling data, not complete data packages before review.
• Surrogate markers (like antibody titers), instead of real clinical endpoints.
• Abbreviated toxicology, because the platform’s safety is treated as settled.
• Overlapping trials (e.g. overlapping Phase 2/3) with minimal long-term follow-up.
• Automatic eligibility for future versions, since they are treated as “updates” built on an accepted scaffold.

Once FDA declared LNP-mRNA a “platform,” the core delivery system stopped being re-examined. New products simply inherited its prior blessing and skipped the foundational safety work.

This administrative sleight-of-hand built a permanent conveyor belt:

Platform accepted → Less data → Faster approvals → More products → More institutional investment → Harder to stop.

This is why Covid boosters, RSV mRNA, mRNA flu, and now sa-mRNA move forward so easily—not because they’ve solved their safety issues, but because the platform itself was pre-cleared.

And unless that original decision is reversed, the belt will keep running.

Why It’s Still Moving Now — Even Under “Reformers”

If the past four years proved anything, it is this: once a technology is blessed as a government-backed platform, it keeps moving no matter who wins an election.

By the time RFK Jr., Makary, and Bhattacharya took office in January 2025, the key mRNA approvals were already locked in:

• Covid mRNA vaccines had been fully licensed (2021–2023) and folded into an annual booster cycle.
• Moderna’s mRNA RSV vaccine (mRESVIA) had been initially approved in 2024 for adults 60+, then expanded to at-risk adults 18-59 in June 2025.
• Multiple mRNA flu candidates were in Fast Track or late-phase trials, effectively queued for approval.
• Sa-mRNA (self-amplifying mRNA) programs backed by BARDA, CEPI, and DoD had moved through Phase 1–2.

· Arcturus’s sa-mRNA Covid vaccine, ARCT-154—already approved in Japan—continues moving through U.S. trials under the same inherited platform shortcuts.

The reformers did not personally greenlight these products. They walked into a regulatory architecture in which the platform itself—not each individual vaccine—was treated as “already proven safe.”

They have made one significant move: RFK Jr.’s HHS cancelled 22 BARDA-funded mRNA contracts, cutting off hundreds of millions in federal money for new government-backed mRNA projects. But that step has limits. It slows federal sponsorship and biodefense-style development. It does not stop private companies from pursuing mRNA products, nor does it dismantle the FDA’s platform-based shortcuts.

Meanwhile, the machinery built between 2020 and 2024 remains intact. Guidance documents, expedited pathways, review teams, and global expectations all still rest on the assumption that mRNA is the future. PREP Act immunity still shields Covid countermeasures. NIH still holds mRNA-related patents. Pharma still has billions invested in the pipeline.

Could the reformers intervene more aggressively? Yes. They could demand new biodistribution and pharmacokinetic studies, reclassify mRNA as higher-risk gene-transfer technology, suspend platform shortcuts, or insist on full toxicology for every new product.

But doing so would mean publicly acknowledging that the original platform approval was reckless—and that millions may have been harmed by a system their own agencies now oversee.

That admission would collide with the biodefense establishment, entrenched career leadership, global pharma partnerships, and international agreements that all assume mRNA is permanent. It would trigger political, financial, and legal shockwaves.

So far, they have not chosen that collision.

The Next Step: Self-Amplifying mRNA — More Expression, More Persistence, More Unknowns

If the original mRNA platform raised red flags, its successor—self-amplifying mRNA (sa-mRNA)—raises even more urgent ones. This technology copies itself inside a person’s cells, driving far higher antigen production for much longer periods and with far less predictability. A small dose becomes a large internal payload—by design.

For biodefense, this is “efficient.”

For human physiology, it magnifies every unresolved concern: LNP biodistribution to vital organs, immune disruption, autoimmune signaling, and a new layer of dose unpredictability where small differences in exposure can produce large, nonlinear outcomes.

These issues were flagged in the pre-Covid literature. None were resolved.

Yet in April 2025, FDA career staff under Peter Marks granted Fast Track status to Arcturus’s sa-mRNA H5N1 influenza vaccine (ARCT-2304), treating this far more aggressive technology as a routine extension of the existing platform—no advisory-committee debate, no new biodistribution studies, no reproductive toxicology, no long-term review.

This is not caution.

It is acceleration—built on a platform that was never required to prove its safety in the first place.

How to Sell an Unsafe Platform: Covid 2.0

When a technology cannot be defended on data, institutions turn instead to managing perception. Increasingly, the concern is not whether mRNA platforms carry unresolved risks, but whether the public believes they do.

A recent study by Xu et al. in npj Vaccines illustrates this pivot. The authors used large-language-model AI to analyze millions of vaccine-related posts on X/Twitter and categorize users based on their sentiment toward vaccines — including toward “emerging technologies such as mRNA-based medicines and therapeutics.” The study found globally negative sentiment toward mRNA, and its purpose was not to interrogate safety but to help health agencies “identify priority areas” for “tailored communication strategies” for different public segments.

The paper treats skepticism as an obstacle to be mapped and managed — not as a signal worth investigating.

As new mRNA products advance, this style of sentiment analysis and targeted messaging is becoming a central tool of public-health communication: not open debate, not transparent data, but strategic shaping of perception.

Corporate media has also already revived the familiar script:

“mRNA will revolutionize vaccines.”

“Platform shots are remarkably safe.”

“Updates can be produced in 100 days.”

These slogans run directly against published data, but accuracy is beside the point. The goal is to recreate the illusion of consensus that defined the Covid mRNA shot roll-out—one narrative, one voice, dissent treated as contamination rather than contribution.

On social platforms, censorship has simply evolved. Deplatforming has been replaced by quieter tools: shadow throttling, downranking keywords, “friction” screens, and AI-generated influencer content designed to drown out competing messages. The tactic is the same: reduce visibility rather than confront objections.

If the mRNA platform were unquestionably safe, none of this would be necessary. Agencies would welcome debate, publish raw data, and invite independent review. Instead, they are constructing a fresh layer of narrative control to shepherd the platform into its next phase.

Covid 2.0 is not a virus—it is an updated messaging architecture.

Why the Platform Won’t Be Walked Back Voluntarily—and What Can Be Done

The mRNA platform is no longer just a scientific question. It is the keystone of a much larger structure: biodefense doctrine, global vaccine policy, pharmaceutical pipelines, NIH royalty schemes, and political reputations on both sides of the aisle.

If FDA or HHS admitted tomorrow that the platform itself poses unacceptable risks, the consequences would be explosive. Regulatory processes would be exposed as structurally unsafe. Both Democratic and Republican administrations would face questions about their role. Pharma stocks and global contracts premised on mRNA would be shaken. Injury claims would gain new force. The PREP shield would become a symbol of institutional betrayal.

Add to that the national-security angle: DARPA, BARDA, and DoD now treat mRNA not primarily as a medical tool, but as a rapid-deployment asset in the biodefense arsenal. To abandon the platform would be to admit that the United States built its pandemic strategy on unstable ground.

For all these reasons, the system will not walk back the platform on its own. It is structurally incentivized to defend it—no matter how strong the evidence of harm becomes.

That does not mean nothing can change. It means change will not come from inside the agencies. It will come, if at all, from outside pressure.

There are only three levers that reliably move entrenched systems:

1. Public refusal. When enough people decline a product, mandates crumble, markets shift, and politicians lose cover. Covid already showed that noncompliance can spread faster than propaganda.
2. Litigation and discovery. Even with PREP immunity, lawsuits can target fraud, censorship, collusion, and civil-rights violations. Discovery is the system’s greatest fear, because it reveals what officials knew and when they knew it.
3. Targeted demands for structural reform. Pressure must focus on specific pressure points: PREP Act reform, emergency-power limits, transparency on LNP composition, platform-level toxicology requirements, NIH royalty disclosure, and the separation of biodefense from civilian public health.

The mRNA platform will not fall because a committee has a change of heart. It will fall, if it falls, because enough people refuse to participate in the lie and insist on accountability.

The system may be locked—the public is not.

If the platform is ever going to be paused, it will be because citizens, doctors, researchers, and injured patients refuse to be silent, refuse to comply, and refuse to let the machinery roll forward without a fight.

**

Rita Barnett-Rose is a medical freedom attorney and former law school professor. She advocates for informed consent, bodily autonomy, and children’s health.

For Further Reading

Halm, E.A., et al. “The Novelty of mRNA Viral Vaccines and Potential Harms: A Scoping Review.” Clinical and Experimental Vaccine Research (2023). A broad review outlining mechanistic concerns, novelty-related risks, and gaps in long-term data for mRNA platforms.

Pfizer EMA Biodistribution Report (2020). Japanese pharmacokinetics data submitted to the European Medicines Agency, showing lipid nanoparticle distribution to liver, spleen, ovaries, adrenal glands, and other organs following injection.

Lerman, Debbie, The Deep State Goes Viral (Brownstone Institute, 2024). A thoroughly documented investigation into the biodefense architecture behind mRNA’s rise, and the regulatory decisions that positioned mRNA as a preferred government countermeasure.

Xu, J. et al. “Mapping global public perspectives on mRNA vaccines and therapeutics.” npj Vaccines, 9, 218 (2024). A global AI-driven analysis showing widespread negative sentiment toward mRNA vaccines and calling for targeted communication strategies to increase public acceptance.